...were maintained during the second year of treatment in patients treated with once-weekly 0.5 mg/kg LB03002...
...hormone (rhGH) for 12 months before switching to LB03002 for an additional 12 months. Specifically, LB03002...
...and 2 years of 11.72 and 8.33 cm/year, respectively. In patients who switched over to LB03002...

...III data YE10 Bioton S.A./LG Life Sciences Ltd. (KSE:068870) Sustained release recombinant human growth hormone (LB03002...

...double-blind, European and U.S. Phase III trial in 152 adults with GHD showed that subcutaneous LB03002...
...LB03002 also significantly increased lean body mass vs. placebo (2.09 kg vs. 0.7 kg, p<=0.0005). LB03002...
...S.A. , Warsaw, Poland LG Life Sciences Ltd. (KSE:068870), Seoul, South Korea Product: SR-rhGH ( LB03002...

...and U.S. Phase III trial in 152 adults with growth hormone deficiency showed that subcutaneous LB03002...
...meeting in Washington. An MAA submission for the sustained release recombinant human growth hormone ( SR-rhGH...

...mg/kg of weekly LB03002 or 0.03 mg/kg of daily rhGH for the first year. All LB03002...
...patients switched in the third year to 0.5 mg/kg weekly LB03002. The middle dose of LB03002...
...S.A. , Warsaw, Poland LG Life Sciences Ltd. (KSE:068870), Seoul, South Korea Product: SR-rhGH ( LB03002...

...Bioton (Warsaw, Poland) said all 3 dosages of weekly LB03002 resulted in sustained growth that was...
...in a Phase II/III trial in 51 previously untreated children with growth hormone deficiency (GHD). LB03002...
...MAA to EMEA in 2009. Bioton's BioPartners GmbH subsidiary holds rights to develop and commercialize LB03002...